These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71. Primary plasma cell leukemia presented with atypical flower-like morphology. Jakovic L; Jovanovic J; Kurtovic NK; Fekete MD; Bogdanovic A Int J Lab Hematol; 2024 Jun; 46(3):425-426. PubMed ID: 38243765 [No Abstract] [Full Text] [Related]
72. First reported case of leukocytapheresis in plasma cell leukemia. Godbey EA; Dalton JB; Lai G; Sanford KW; Roseff SD Transfusion; 2020 Jan; 60(1):11-12. PubMed ID: 31682280 [No Abstract] [Full Text] [Related]
73. Primary plasma cell leukaemia presenting with flower-shaped nuclei. De Miguel Sánchez C; Robles de Castro D; Pisón Herrero C; Pérez Persona E; Salcedo Cuesta L; Guinea de Castro JM Br J Haematol; 2021 May; 193(4):689. PubMed ID: 33618433 [No Abstract] [Full Text] [Related]
74. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175 [TBL] [Abstract][Full Text] [Related]
75. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191 [TBL] [Abstract][Full Text] [Related]
76. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Stein CK; Pawlyn C; Chavan S; Rasche L; Weinhold N; Corken A; Buros A; Sonneveld P; Jackson GH; Landgren O; Mughal T; He J; Barlogie B; Bergsagel PL; Davies FE; Walker BA; Morgan GJ Oncotarget; 2017 Apr; 8(17):27854-27867. PubMed ID: 28427158 [TBL] [Abstract][Full Text] [Related]
77. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. Aguiar PM; de Mendonça Lima T; Colleoni GWB; Storpirtis S Crit Rev Oncol Hematol; 2017 May; 113():195-212. PubMed ID: 28427509 [TBL] [Abstract][Full Text] [Related]
78. Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party. Sobh M; Michallet M; Dubois V; Iacobelli S; Koster L; Van Biezen A; Fegueux N; Tabrizi R; Finke J; El-Cheikh J; Schipperus M; Meijer E; von dem Borne P; Petersen E; Russell N; Tholouli E; Passweg J; Garban F; Maertens J; Chevalier P; Maillard N; Volin L; Francois S; Lioure B; Beguin Y; Gluckman E; Ruggeri A; Garderet L; Kröger N Haematologica; 2017 Jul; 102(7):e271-e274. PubMed ID: 28428268 [No Abstract] [Full Text] [Related]
79. The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine. Knobloch J; Jungck D; Koch A Curr Mol Med; 2017; 17(2):108-117. PubMed ID: 28429672 [TBL] [Abstract][Full Text] [Related]